Can Neuron Specific Enolase Be a Diagnostic Biomarker for Neuronal Injury in COVID-19?
Latha Ganti, Enrique Serrano, Hale Z Toklu, Latha Ganti, Enrique Serrano, Hale Z Toklu
Abstract
Neuron specific enolase (NSE) is a biomarker for neuronal injury. However, increased levels in cerebrospinal fluid (CSF) and serum is associated with the clinical outcome in patients with head injury, ischemic stroke, intracerebral hemorrhage, cardiac arrest, anoxic encephalopathy, encephalitis, brain metastasis, and status epilepticus. Recently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which started in China, rapidly evolved into the coronavirus disease 2019 (COVID-19) pandemic. Patients with COVID-19 have a wide range of symptoms varying from mild upper respiratory symptoms to severe illness requiring mechanical ventilation. While coronaviruses primarily target the human respiratory system, neurological symptoms are also observed in some patients. These include symptoms such as loss of taste and olfaction and diseases like cerebrovascular disorders including ischemic stroke and hemorrhages, encephalopathies, Guillain-Barré syndrome and acute disseminated encephalomyelitis. Here we report an observation from a patient whose NSE levels increased approximately four-fold in CSF. This finding was accompanied by increased white blood cell count and elevated protein in CSF indicating neuroinflammation. Thus, we suggest that NSE may be used as a CSF biomarker in COVID-19 patients with encephalopathy.
Keywords: cerebrospinal fluid; covid-19; csf; neuron specific enolase; nse; sars-cov2.
Conflict of interest statement
The authors have declared that no competing interests exist.
Copyright © 2020, Ganti et al.
Figures
References
- Neuron-specific enolase as a biomarker: biochemical and clinical aspects. Isgrò MA, Bottoni P, Scatena R. Adv Exp Med Biol. 2015;867:125–143.
- New insights into the role of neuron-specific enolase in neuro-inflammation, neurodegeneration, and neuroprotection. Haque A, Polcyn R, Matzelle D, Banik NL. Brain Sci. 2018;8
- Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Lamers KJ, Vos P, Verbeek MM, Rosmalen F, van Geel WJ, van Engelen BG. Brain Res Bull. 2003;61:261–264.
- Peripheral markers of brain damage and blood-brain barrier dysfunction. Marchi N, Rasmussen P, Kapural M, et al. Restor Neurol Neurosci. 2003;21:109–121.
- Use of neuron-specific enolase for assessing the severity and outcome in patients with neurological disorders. Lima JE, Takayanagui OM, Garcia LV, Leite JP. Braz J Med Biol Res. 2004;37:19–26.
- Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. Baig AM, Khaleeq A, Ali U, Syeda H. ACS Chem Neurosci. 2020;11:995–998.
- The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. Li YC, Bai WZ, Hashikawa T. J Med Virol. 2020;92:552–555.
- Cerebrospinal fluid (CSF) analysis and interpretation in neurocritical care for acute neurological conditions. Hrishi AP, Sethuraman M. Indian J Crit Care Med. 2019;23:115–119.
Source: PubMed